79 results
8-K
EX-99.1
ARVN
Arvinas Inc
16 May 24
Regulation FD Disclosure
6:05am
. Risks and uncertainties include, among other things, uncertainties regarding the commercial success of IBRANCE; the uncertainties inherent in research … and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory
8-K
EX-99.1
ARVN
Arvinas Inc
7 May 24
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
7:02am
options of $1.8 million.
Research and Development Expenses: Research and development expenses were $84.3 million for the quarter ended March 31 … , 2024, as compared with $95.3 million for the quarter ended March 31, 2023. The decrease in research and development expenses of $11.0 million
8-K
EX-99.1
9l8698v4sxc2wsf8
27 Feb 24
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
7:02am
S-3ASR
z47lj52srpnljlrzszz
8 Dec 23
Automatic shelf registration
9:16am
8-K
EX-99.1
drfgx
6 Dec 23
Regulation FD Disclosure
7:01am
S-3ASR
ko89tyj ij
7 Nov 23
Automatic shelf registration
5:24pm
8-K
EX-99.1
ardklzal
7 Nov 23
Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update
7:03am
8-K
EX-99.1
fggb621e0b4
8 Aug 23
Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update
7:03am
8-K
EX-99.1
k6cqb
5 May 23
Arvinas Reports First Quarter 2023 Financial Results and Provides Corporate Update
7:30am
8-K
EX-99.1
cfk yb3b2exa
9 Nov 22
Arvinas Reports Third Quarter 2022 Financial Results and Provides Corporate Update
7:28am
8-K
EX-99.1
fmlccl5olhz qwihnk6
5 Aug 22
Arvinas Reports Second Quarter 2022 Financial Results and Provides Corporate Update
4:12pm